The Paramount BioSciences’ executive team, through its affiliates, is supported by approximately 80 in-house professionals, including drug developers, MDs, PhDs, finance professionals, attorneys, accountants, and analysts. Each of these individuals provides Paramount BioSciences’ portfolio companies with a wide-range of professional and support services.

Lindsay Rosenwald, M.D.
Chairman and Chief Executive Officer

• Founder of Paramount BioSciences
• More than 20 years of experience in creating, financing, and investing in biotechnology and life-sciences companies in his role as Founder and Chief Executive Officer of Paramount BioSciences
• M.D., Temple Medical School; Founder, The Rosenwald Foundation

Jay Lobell, J.D.
President and Chief Operating Officer

• Former partner at law firm Covington & Burling, where he provided regulatory, litigation, and business advice to corporations, financial institutions, and individuals
• Significant experience in financial, regulatory, and deal-structuring in health care and biotechnology transactions
• J.D., Yale Law School; Senior Editor, Yale Law Journal

Bertrand Liang, M.D.
Vice Chairman

• More than 15 years of experience in the biotechnology industry
• Previously corporate venture capitalist at Biogen Idec; Development Site Head, Biogen Idec
• Led the development of several products, including Neulasta (a $1bn product) and the life-cycle plan of Rituxan
• M.D., Northwestern University Medical School

Russell Ellison, M.D.
Executive Vice President, Paramount BioSciences

• Twenty-eight years of senior management pharmaceutical experience in drug development and commercialization
• Former Vice President of Clinical Development at Fibrogen, Inc. and also served as the U.S. Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, USA
• Former U.S. Vice President, Medical Affairs and Chief Medical Officer of Hoffmann La Roche
• M.D., University of British Columbia and an MSc (with distinction) from The London School of Tropical Medicine and Hygiene

Margery Fischbein
Executive Vice President, Head of Mergers and Acquisitions, Paramount BioSciences

• More than 20 years of biotechnology and life-sciences mergers and acquisitions and alliance management experience
• Former Head of Business Development, Strategic Planning and Alliance Management of Human Genome Sciences and also served as Head of Business Development for ImClone Systems
• Former Managing Director in the Investment and Corporate Banking Divisions of Citigroup and JP Morgan Chase and SVP at Lehman Brothers
• M.B.A., Harvard Business School and B.A., Harvard University

John Graham
President, Paramount Corporate Development

• Over 20 years of experience in pharmaceuticals in various management, operational, and strategic positions
• Formerly principal at Ernst & Young Life Sciences, vice president at Genzyme Corp., and vice president at Aventis S.A.
• B.Sc., Biochemistry, Imperial College of London